key: cord-0714787-m4al65nq
authors: Tsai, Ming-Shao; Yang, Yao-Hsu; Lin, Yu-Shih; Chang, Geng-He; Hsu, Cheng-Ming; Yeh, Reming-Albert; Shu, Li-Hsin; Cheng, Yu-Ching; Liu, Hung-Te; Wu, Yu-Huei; Wu, Yu-Heng; Shen, Rou-Chen; Wu, Ching-Yuan
title: GB-2 Blocking the Interaction between ACE2 and Wild Type and Mutation of Spike Protein of SARS-CoV-2
date: 2021-08-05
journal: Biomed Pharmacother
DOI: 10.1016/j.biopha.2021.112011
sha: 2e1bd7bb814eb108801921965074e75b9b039f0f
doc_id: 714787
cord_uid: m4al65nq

Since the start of the outbreak of coronavirus disease 2019 in Wuhan, China, there have been more than 150 million confirmed cases of the disease reported to the World Health Organization. The beta variant (B.1.351 lineage), the mutation lineages of SARS-CoV-2, had increase transmissibility and resistance to neutralizing antibodies due to multiple mutations in the spike protein. N501Y, K417N and E484K, in the receptor binding domain (RBD) region may induce a conformational change of the spike protein and subsequently increase the infectivity of the beta variant. The L452R mutation in the epsilon variant (the B.1.427/B.1.429 variants) also reduced neutralizing activity of monoclonal antibodies. In this study, we discovered that 300 μg/mL GB-2, from Tian Shang Sheng Mu of Chiayi Puzi Peitian Temple, can inhibit the binding between ACE2 and wild-type (Wuhan type) RBD spike protein. GB-2 can inhibit the binding between ACE2 and RBD with K417N-E484K-N501Y mutation in a dose-dependent manner. GB-2 inhibited the binding between ACE2 and the RBD with a single mutation (K417N or N501Y or L452R) except the E484K mutation. In the compositions of GB-2, glycyrrhiza uralensis Fisch. ex DC., theaflavin and (+)-catechin cannot inhibit the binding between ACE2 and wild-type RBD spike protein. Theaflavin 3-gallate can inhibit the binding between ACE2 and wild-type RBD spike protein. Our results suggest that GB-2 could be a potential candidate for the prophylaxis of some SARS-CoV-2 variants infection in the further clinical study because of its inhibition of binding between ACE2 and RBD with K417N-E484K-N501Y mutations or L452R mutation.

Since the start of the outbreak of coronavirus disease 2019 in Wuhan, China, there have been more than 150 million confirmed cases of the disease, including more than 3 million deaths worldwide, reported to the World Health Organization. SARS-CoV-2 is the seventh human coronavirus and the first human coronavirus with global pandemic disease [1] . In severe COVID-19, many patients suffered from severe pneumonia and acute respiratory distress syndrome. Moreover, older patients who had co-morbidities such as diabetes mellitus, cardiovascular disease, and dementia, such as Alzheimer'slike dementia, have higher rates of deaths in COVID-19 [2, 3] .

In coronaviruses, spike protein on the surface envelope of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for promoting viral entry into host cells [4] . The spike protein is composed of two functional subunits: the S1 subunit that binds to host cell receptors, and the S2 subunit that mediates the fusion of the viral and host cellular membranes. The distal part of the S1 subunit contains the receptor J o u r n a l P r e -p r o o f binding domain (RBD) that directly binds to the peptidase domain of angiotensinconverting enzyme 2 (ACE2) [5, 6] . Moreover, heparan sulfate may facilitates SARS-CoV-2 spike protein binding to ACE2 [7] . RBD of SARS-CoV-2 spike protein binds to the three sub-domains through amino acids 22-42, 79-84, and 330-393 of ACE2 of the human host cells to initiate entry [8] . Moreover, the direct area of contact between RBD and ACE2 includes several regions. Gln498, Thr500, and Asn501 residues of the amino terminus (N) of RBD form several hydrogen bonds with the Tyr41, Gln42, Lys353, and Arg357 residues of ACE2. The Lys417 and Tyr453 residues of RBD interact with the Asp30 and His34 residues of ACE2, respectively [5] . Moreover, the S subunit of SARS-CoV-2 contains a cleavage site for furin and other proteases and accelerates viral entry [9] .

Until now, most current mono-antibodies, vaccines and protease inhibitors are developing by targeting the structure of SARS-CoV-2 [10, 11] . However, SARS-CoV-2 belongs to the family of RNA viruses, which have higher mutation rates than DNA viruses [12, 13] . Among the mutation lineages of SARS-CoV-2, the beta variant (B.1.351 lineage), which was first detected in South Africa, has demonstrated higher transmissibility and resistance to neutralizing antibodies due to multiple mutations in the spike protein [14, 15] . The SARS-CoV-2 beta variant contains nine mutations in the J o u r n a l P r e -p r o o f spike protein: D614G, Δ242-Δ244, and R246I in the N-terminal domain; three mutations (K417N, E484K, and N501Y) in the RBD; and one mutation (A701V) near the furin cleavage site [14] . Among them, N501Y, K417N, and E484K in the receptor binding motif of the RBD region may induce a conformational change in the spike protein and subsequently increase the infectivity of beta variant [15] . Moreover, beta variant is resistant to neutralization by most monoclonal antibodies against the Nterminal domain and multiple individual monoclonal antibodies against the receptorbinding motif of the RBD due to E484K mutation [14] . Beta variant is also refractory to neutralization by sera from vaccinated persons [14] . In addition, the SARS-CoV-2 epsilon variant (the B.1.427/B.1.429 variant of concern) was first reported for in California and has been detected in more than 30 countries till now [16, 17] . Moreover, L452R mutation in spike protein of epsilon variant could increase infectivity in vitro and loss neutralizing activity of monoantibodies [17] [18] [19] . These results suggest that the protective effects of current SARS-CoV-2 vaccines and monoclonal antibody therapies are threatened by these variants.

In our previous studies, we discovered that GB-2, a prophylaxis formula against SARS-CoV-2 and from Tian Shang Sheng Mu of Chiayi Puzi Peitian Temple in Taiwan, inhibited ACE2 mRNA expression and ACE2 and TMPRSS2 protein expression in J o u r n a l P r e -p r o o f HepG2 and 293T cells and decreased the ACE2 expression level of lung and kidney tissue in the animal model [20] . However, the effect of GB-2 on the interaction between ACE2 and wild-type and mutation-type spike proteins of SARS-CoV-2 remains unclear.

In this study, we investigated the effects of GB-2 and the index compounds of Camellia sinensis var. assamica extract on the interaction between ACE2 and wild-type and mutation-type spike proteins of SARS-CoV-2. J o u r n a l P r e -p r o o f

The flow cytometry analysis of ACE2-S Binding were performed as described previously [22] . Briefly, 293T cells were transfected with pCEP4-MYC-ACE2 or pcDNA3-SARS-CoV-2-S-RBD-sfGFP plasmids (500 ng DNA per ml of culture at 2 × was used for all calculations.

293T cells was used as a model of SARS-CoV-2 entry in the previous studies [22, 23] .

To investigate the effect of GB-2 on the interaction between ACE2 and the spike protein of SARS-CoV-2, we used 293T cells as the model in our study. First, we used a 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide assay to investigate the cytotoxicity of GB-2 to 293T cells. Our results showed that GB-2 treatment with concentrations 200-300 μg/mL had not inhibited the cell variability of the 293T cells after the indicated number of hours (Fig. 1A) . These data suggested that 200-300 μg/mL GB-2 did not have significant cytotoxicity against the cell variability of the 293T cell line.

To investigate the effect of GB-2 on the interaction between ACE2 and the spike protein of wild-type SARS-CoV-2, we used a spike/ACE2 inhibitor screening assay kit to determine the impact on the binding of Spike protein to the ACE2 receptor by GB-2 [10] . As illustrated in Fig. 1B , we found that incubating the spike RBD with GB-2 resulted in blocking of the binding of the wild-type RBD the spike protein to the ACE2 J o u r n a l P r e -p r o o f receptor in a concentration-dependent manner over the concentration range 100 to 300 μg/mL (Fig. 1B) .

To confirm the previous results, we used dual-color flow cytometric analysis to investigate ACE2-spike protein binding in 293T cells [22] . 293T cells expressing MYC-tagged ACE2 were then incubated with medium containing the wild-type RBD of SARS-CoV-2 fused to superfolder green fluorescent protein [24] . After treatment of the cells with the indicated drugs, populations of cells that expressed MYC-tagged ACE2 at the cell surface with high or low binding to RBD were collected through fluorescenceactivated cell sorting. After treatment of the cells with 300 μg/mL GB-2, the number of 293T cells with low binding to RBD was significantly increased in both ACE2-positive cells and the top population (Fig. 1C, D) . These results suggested that 300 μg/mL GB-2 inhibited the binding between ACE2 and the wild-type RBD of the spike protein. Fig. 2A, B) .

The number of 293T cells with high binding to the RBD with a triple mutation (K417N-E484K-N501Y) was also decreased in ACE2-positive cells and the top population in a J o u r n a l P r e -p r o o f dose-dependent manner ( Fig. 2A, B) . These results suggested that 200-300 μg/mL GB-2 inhibited the binding between ACE2 and RBD with a triple mutation (K417N-E484K-N501Y). (Fig. 3E, F) . These results suggested that 200-300 μg/mL GB-2 inhibited the binding between ACE2 and the RBD with a single mutation (K417N or N501Y) except the E484K mutation.

The previous studies reported that L452R mutation could increase transmissibility, infectivity, and resist to antibody neutralization [17] [18] [19] . Because 300 μg/mL GB-2 has the best inhibitory effect on the binding between ACE2 and the RBD. Next, we also investigated the effect of 300 μg/mL GB-2 on the interaction between ACE2 and L452R mutation of the RBD through dual-color flow cytometric analysis. After treatment of the cells with 300 μg/mL GB-2, the number of 293T cells with low binding to the RBD with L452R mutation was significantly increased in both ACE2-positive cells and the top population in a dose-dependent manner (Fig. 3G, H) . The number of 293T cells with high binding to the RBD with L452R mutation was also decreased in both ACE2positive cells and the top population in a dose-dependent manner (Fig. 3G, H) . These results suggested that 300 μg/mL GB-2 could inhibit the interaction between ACE2 and the RBD with L452R mutation. Our results indicate that 300 μg/mL GB-2 inhibited the binding between ACE2 and the wild-type RBD of the spike protein (Fig. 1B-D) .

However, the effect of GU on the interaction between ACE2 and the wild-type RBD of the spike protein is unclear. To investigate the effect of GU on the interaction between J o u r n a l P r e -p r o o f ACE2 and the spike protein of wild-type SARS-CoV-2, we used a spike/ACE2 inhibitor screening assay kit to discover the impact on the binding of spike protein to the ACE2 receptor [21] . Using the kit, we found that GU could not block the binding of the wild type of the RBD of the spike protein to the ACE2 receptor (Fig. 4A ).

Next, we investigated the effect of the index compounds of C. sinensis var. assamica extract, (+)-catechin (Fig. 4B ) on the binding between ACE2 and the wild type of the RBD of the spike protein. Using a spike/ACE2 inhibitor screening assay kit, we found that (+)-catechin could not block the binding of the wild type the RBD of the spike protein to the ACE2 receptor (Fig. 4C) .

Several reports showed that theaflavin and the similar structures, index compounds extracted from C. sinensis var. assamica, could be the SARS-CoV-2 inhibtors through in vitro and in-silico methods [28] [29] [30] [31] . Because the effect of theaflavin on interaction between ACE2 and spike protein is still unclear, we investigated the binding between ACE2 and spike protein. First, the high-performance liquid chromatography (HPLC) results showed that the concentration of theaflavin in GB-2 was 0.19837% (wt/wt; Fig.   4E , F). Using the kit, we also found that theaflavin could not block the binding of the Wild type the RBD of the spike protein to the ACE2 receptor (Fig. 4G) . These results suggested that both GU and theaflavin cannot inhibit the binding between ACE2 and the J o u r n a l P r e -p r o o f wild-type RBD of the spike protein.

Using a spike/ACE2 inhibitor screening assay kit, we also investigated the effect of theaflavin 3-gallate (Fig. 5A) , another index compound of C. sinensis var. assamica extract, on the binding between ACE2 and the wild type the RBD of the spike protein.

Our HPLC results showed that the concentration of theaflavin 3-gallate in GB-2 was 0.39358% (wt/wt; Fig. 5B , C). Using the kit, we found that only 50 μg/mL of theaflavin 3-gallate could partially block the binding of the wild type of the RBD of the spike protein to the ACE2 receptor (Fig. 5D) . These results suggested that a higher concentration of theaflavin 3-gallate can partially inhibit the binding between ACE2 and the wild-type RBD of the spike protein.

Recent studies have reported that SARS-CoV-2 alpha variant in the United Kingdom and beta variant in South Africa have significantly higher infectivity than other strains of SARS-CoV-2 [14, 32] . For beta variant, approximately 77% of mutations are located in the spike protein [32] . These mutations on spike proteins may affect the vaccine efficacy and treatments more than other variants. For epsilon variant, the two B. 1.427 and B.1.429 lineages have the same spike protein mutations, inclunding S13I and J o u r n a l P r e -p r o o f W152C in the NTD and L452R in the RBD [17] . Moreover, L452R mutation of epsilon variant reduced neutralizing activity of several RBD-specific monoclonal antibodies [18] .

Because these N501Y, K417N, E484K and L452R mutations in RBD play the important role in immune evasion, we focused on the effect of GB-2 on these mutations.

Both alpha and beta variants have the N501Y mutation. The N501Y mutation in the RBD domain of the spike protein increases both the binding affinity of the RBD to the ACE2 receptor and the viral transmission rate of both alpha and beta variants [5, 25, 32] .

We discovered that GB-2 can block the binding between ACE2 and RBD with a single mutation (N501Y). The results suggested that GB-2 could decrease the viral transmission rate of both alpha and beta variants with the N501Y mutation. L452R mutation is the imporant mutatnt in RBD of epsilon variant. For L452R, previous studies showed that the L452R mutation may stabilize the binding between the spike protein and human ACE2 to increase infectivity [33, 34] . We found that GB-2 can block the binding between ACE2 and RBD with L452R mutation. The results suggested that GB-2 may decrease infectivity of epsilon variant with L452R mutation.

E484K can switch the charge on the flexible loop region of the RBD and induce the formation of new favorable contact. This is possibly why GB-2 cannot affect the binding between ACE2 and the RBD with a single mutation (E484K). In the other mutation, the K417 residue in the RBD of the spike protein of SARS-CoV-2 can interact with ACE2 and enhance the affinity of the virus for the ACE2 receptor. A previous study suggested that the K417N mutation minimally affects this binding between the RBD and the ACE2 receptor [26] . In our results, we also discovered that GB-2 can block the binding between ACE2 and the RBD with a single mutation (K417N) Black tea has the important medicinal values in many countries and areas in the world. The bioactive components form black tea are involved in the prevention and treatment of many diseases, including cardiovascular diseases, malignancy, digestive dysfunction, obesity, diabetes, chronic renal disease and renal fibrosis [35] [36] [37] . In a previous study, epigallocatechin-3-gallate, the major component of green tea, blocked the entry of SARS-CoV-2 with pseudotyped lentiviral vectors and inhibited viral infections in vitro by inhibiting the interaction between the SARS-CoV-2 spike protein and the ACE2 receptor [38] . Another report showed that (−)-gallocatechin gallate, a polyphenol in green tea, disrupted the liquid-liquid phase separation of the SARS-CoV-2 nucleocapsid protein and inhibited SARS-CoV-2 replication [39] . Moreover, another study showed that epigallocatechin-3-gallate and theaflavin inhibited the activity of the SARS-CoV-2 3CL protease [40] . These studies suggest that the tea extract and index compounds could play a major role in the treatment of SAR-CoV-2. However, the effects of the tea extract and index compounds on SARS-CoV-2 variants with mutations remain unclear. In this study, we discovered that GB-2 blocks the binding between ACE2 and RBD with a triple mutation (K417N-E484K-N501Y) and L452R mutation.

J o u r n a l P r e -p r o o f 20 The results suggest that GB-2 may play a useful role in the treatment of or prophylaxis against several variants. However, the further clinical trials of GB-2 and these index compounds should be investigated to confirm the clinical effort, even compare with the current vaccines.

In conclusion, our results suggest that GB-2 could be a candidate for prophylaxis against SARS-CoV-2 different variants infection because of its inhibition of the binding between ACE2 and the RBD with K417N-E484K-N501Y mutations and L452R mutation. However, the exact clinical effect remains unknown. Thus, further clinical research is necessary to confirm the protective effects of GB-2 against SARS-CoV-2 some variants.

Memorial Hospital (Chiayi) to Dr. Ching Yuan Wu. The funding bodies allowed to the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

All data generated or analyzed during this study are indicated in this article (with no patient data). The datasets generated during and /or analyzed during the current study are available from the corresponding author on reasonable request.

Not applicable (not contain any individual person's data).

The authors declare no conflict of interest.

Ching 

Questions concerning the proximal origin of SARS-CoV-2

SARS-CoV-2 pathophysiology and assessment of coronaviruses in CNS diseases with a focus on therapeutic targets

COVID-19, Neuropathology, and Aging: SARS-CoV-2 Neurological Infection, Mechanism, and Associated Complications

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Engaging the spikes: heparan sulfate facilitates SARS-CoV-2 spike protein binding to ACE2 and potentiates viral infection

Possible Transmission Flow of SARS-CoV-2 Based on ACE2 Features

The structural basis of accelerated host cell entry by SARS-CoV-2dagger

Current Status of Multiple Drug Molecules, and Vaccines: An Update in SARS-CoV-2 Therapeutics

Notable sequence homology of the ORF10 protein introspects the architecture of SARS-CoV-2

Why are RNA virus mutation rates so damn high?

The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus

A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology

Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant

SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern

SARS-CoV-2 B.1.617 mutations L452 and E484Q are not synergistic for antibody evasion

GB-2 inhibits ACE2 and TMPRSS2 expression: In vivo and in vitro studies

Hijacking SARS-CoV-2/ACE2 Receptor Interaction by Natural and Semi-synthetic Steroidal Agents Acting on Functional Pockets on the Receptor Binding Domain

Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

Engineering and characterization of a superfolder green fluorescent protein

Cryoelectron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies

Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding

Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy

Elucidation of the inhibitory activity of plant-derived SARS-CoV inhibitors and their potential as SARS-CoV-2 inhibitors

Significant Inactivation of SARS-CoV-2 In Vitro by a Green Tea Catechin, a Catechin-Derivative, and Black Tea Galloylated Theaflavins

In-silico evaluation of bioactive compounds from tea as potential SARS-CoV-2 nonstructural protein 16 inhibitors

Black tea bioactives as inhibitors of multiple targets of SARS-CoV-2 (3CLpro, PLpro and RdRp): a virtual screening and molecular dynamic simulation study

Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19

Systemic effects of missense mutations on SARS-CoV-2 spike glycoprotein stability and receptor-binding affinity

Potential Bioactive Components and Health Promotional Benefits of Tea (Camellia sinensis)

Modulation of Glucose Metabolism by Leaf Tea Constituents: A Systematic Review of Recent Clinical and Pre-clinical Findings

Molecular Mechanisms of Epigallocatechin-3

Gallate for Prevention of Chronic Kidney Disease and Renal Fibrosis: Preclinical Evidence

The green tea catechin epigallocatechin gallate inhibits SARS-CoV-2 infection

GCG inhibits SARS-CoV-2 replication by disrupting the liquid phase condensation of its nucleocapsid protein

Tea Polyphenols EGCG and Theaflavin Inhibit the Activity of SARS-CoV-2 3CL-Protease In Vitro

A) 293T analysis, the top population were chosen from the ACE2-positive population. Then, two subsets of the ACE2-positive population were collected: the top population (nCoV-S-High sort, red gate) and the bottom population (nCoV-S-Low sort, green gate) based on the fluorescence of bound RBD (N501Y(A), K417N(C), E484K(E) or L452R(G))-sfGFP relative to ACE2 surface expression

Asterisks (*) mark samples significantly different from control group with p<0.05)

The indicated compounds were tested to evaluate their ability to inhibit the binding of spike protein to immobilized ACE2 by the ACE2/SARS-CoV-2 spike inhibitor screening assay. (B) The structure of (+)-catechin. (D) The structure of theaflavin

Writing-Original draft preparation

 GB-2 inhibit the binding between ACE2 and wild-type (Wuhan type) RBD spike protein

 GB-2 inhibit the binding between ACE2 and RBD with triple mutation (K417N-E484K-N501Y)

2 inhibit the binding between ACE2 and the RBD with a single mutation (K417N or N501Y or L452R) except the E484K mutation

ex DC. extract, theaflavin and (+)-catechin cannot inhibit the binding between ACE2 and wild-type RBD spike protein

 Theaflavin 3-gallate can inhibit the binding between ACE2 and wildtype RBD spike protein

2 and theaflavin 3-gallate act as potential candidate for the prophylaxis of some SARS-CoV-2 variants infection in the further

The authors acknowledge the Health Information and Epidemiology Laboratory at the 

Financial support was obtained from grant MOST 109-2320-B-182-021-MY3 from Ministry of Science and Technology (TW) and CORPG6K0211 from Chang Gung